Nrx Pharmaceuticals, INC Schedule 13G passive stakes
Filed when an investor crosses five percent without intending to seek control — the passive counterpart to a 13D.
NASDAQ
Anson Funds Management LP and affiliated entities have reported beneficial ownership of 4.9% of NRX Pharmaceuticals, Inc. common stock, including shares underlying warrants.
NASDAQ
The B Group, Inc., B Group Capital LLC, and Branden B. Muhl have jointly disclosed a 12.62% beneficial ownership stake in NRx Pharmaceuticals, Inc.
NASDAQ
Anson Funds Management LP and related entities have disclosed a 9.3% beneficial ownership stake in NRX Pharmaceuticals, Inc. common stock.
NASDAQ
Anson Funds Management LP and its affiliates have disclosed a 7% passive beneficial ownership stake in NRX Pharmaceuticals, Inc., totaling 1,179,061 shares of common stock.